Refractory B Cell Lymphoma clinical trials

Explore recruiting refractory b cell lymphoma clinical trials.

Recruiting refractory b cell lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory B Cell Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase I/IIa multicentre phase I/IIa study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beauty family transposons to express a chimeric antigenic receptor with anti-CD19 specificity conjugated to the 4-1BB co-stimulatory and signal-transduction region CD3z and huEGFRt (TranspoCART19) in patients with relapsed or refractory B-cell lymphoma.

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

VALYM - A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma

France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Finland, Spain, Denmark, Poland, Germany, France +3 more

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

Germany, Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase I/IIa multicenter study evaluating the safety and efficacy of CAR20(NAP)-T in patients with relapsed/refractory B cell lymphoma (CARMA-01)

Sweden

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Refractory B Cell Lymphoma trials by city

Refractory B Cell Lymphoma clinical trials

Recruiting refractory b cell lymphoma studies right now

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Q702 for the Treatment of Patients With Hematologic Malignancies

Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma